Resectable Esophagogastric Adenocarcinoma clinical trials

Explore recruiting resectable esophagogastric adenocarcinoma clinical trials.

Recruiting resectable esophagogastric adenocarcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Resectable Esophagogastric Adenocarcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

NeoTISLEGA - A phase Ib trial evaluating the safety and activity of neoadjuvant combination of tislelizumab plus FLOT for resectable esophagogastric adenocarcinoma

Germany

Human Pharmacology (Phase I)- Other EU CTIS Study details

NeoART – A phase Ib/II platform trial evaluating the safety and activity of neoadjuvant trastuzumab-deruxtecan containing combination therapies for HER2+, resectable esophagogastric adenocarcinoma

Germany, Austria

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Resectable Esophagogastric Adenocarcinoma trials by city

Resectable Esophagogastric Adenocarcinoma in Toronto Resectable Esophagogastric Adenocarcinoma in Vancouver Resectable Esophagogastric Adenocarcinoma in Montreal Resectable Esophagogastric Adenocarcinoma in Calgary Resectable Esophagogastric Adenocarcinoma in Edmonton Resectable Esophagogastric Adenocarcinoma in Ottawa Resectable Esophagogastric Adenocarcinoma in Winnipeg Resectable Esophagogastric Adenocarcinoma in Quebec City Resectable Esophagogastric Adenocarcinoma in Hamilton Resectable Esophagogastric Adenocarcinoma in Kitchener Resectable Esophagogastric Adenocarcinoma in London Resectable Esophagogastric Adenocarcinoma in Halifax Resectable Esophagogastric Adenocarcinoma in New York Resectable Esophagogastric Adenocarcinoma in Los Angeles Resectable Esophagogastric Adenocarcinoma in Chicago Resectable Esophagogastric Adenocarcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease